Home About us Contact
|
Home About us Contact | ||
|
|
||
New Preparation (new + preparation)
Selected AbstractsChemInform Abstract: New Preparation and Reactions of Arylaluminum Reagents Using Barbier Conditions.CHEMINFORM, Issue 39 2009Hongjun Gao Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a "Full Text" option. The original article is trackable via the "References" option. [source] A New Preparation of Trifluoromethanesulfinate SaltsCHEMINFORM, Issue 43 2007Bernard R. Langlois Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF. [source] From Isocyanides to Trichloropyruvamides: Application to a New Preparation of Oxamide Derivatives.CHEMINFORM, Issue 6 2005Laurent El Kaim Abstract For Abstract see ChemInform Abstract in Full Text. [source] New preparation of gold,silver complexes and optical fibre environmental sensors based on vapochromic [Au2Ag2(C6F5)4(phen)2]nAPPLIED ORGANOMETALLIC CHEMISTRY, Issue 12 2005Asunción Luquin Abstract Complexes [Au2Ag2(C6F5)4L2]n, where L = 1,10-phenanthroline (phen), 2,2,-bipyridine (bipy) or tetrahydrothiophene (tht), have been synthesized by reaction of NBu4[Au(C6F5)2] with Ag(SO3CF3), and the addition of phen or bipy thereafter, or with [Ag(SO3CF3)(tht)]. The organometallic vapochromic material [Au2Ag2(C6F5)4(phen)2]n is isolated as a powder that is able to detect volatile organic compounds such as acetone even in an aqueous solution. The colour of this vapochromic material changes from bright yellow to white in the presence of different donor solvents such as acetone, methanol or ethanol. For the practical construction of an optical fibre sensor, a sol-gel doped with the vapochromic complex was deposited onto one end of a monomode fibre connected to a coupler. The behaviour of the material was studied at different wavelengths and concentrations of acetone vapours and acetone,water solutions. Changes were detected up to 4 dB in the reflected optical power. Copyright © 2005 John Wiley & Sons, Ltd. [source] Testosterone treatment comes of age: new options for hypogonadal menCLINICAL ENDOCRINOLOGY, Issue 3 2006Eberhard Nieschlag Summary Male hypogonadism is one of the most frequent, but also most underdiagnosed, endocrinopathies. However, the required testosterone treatment is simple and very effective if properly administered. Although testosterone has been available for clinical use for seven decades, until quite recently the treatment modalities were far from ideal. Subdermal testosterone pellets require minor surgery for insertion and often cause local problems. The injectable testosterone enanthate, for a long period the most frequently used mode of administration, lasts for two to four weeks, but produces supraphysiological levels initially and low levels before the next injection. The oral testosterone undecanoate has to be taken three times daily, has an uncertain absorption pattern and results in peaks and valleys of serum testosterone levels throughout the day. With the advent of transdermal testosterone preparations, the desired physiological serum levels could be achieved for the first time. Scrotal testosterone patches were the first to fulfil this requirement. These were followed by nonscrotal skin patches, which, however, cause considerable skin reactions including erythema and blisters. Recently introduced, invisible transdermal testosterone gels increased the intervals of application and are now slowly replacing other modalities. A mucoadhesive buccal testosterone tablet with sustained release is also a recent competing modality. Finally, injectable testosterone undecanoate in castor oil was made into a real depot preparation requiring only four injections per year for replacement therapy. These new preparations with a desired pharmacokinetic testosterone profile give the patient a real choice and make treatment easier. Based on pharmacogenetic considerations taking the androgen receptor polymorphism into account, treatment may be individualized for each patient in the future. [source] | ||||||||||